245368-50-7

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Pentene-1-sulfonamide is used as a reagent in the pharmaceutical industry for the synthesis of various heterocyclic compounds. Its unique structure allows it to be a key building block in the creation of a wide range of organic compounds, contributing to the development of new drugs and therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, 4-Pentene-1-sulfonamide is utilized as a reagent for the preparation of different organic chemicals. Its ability to participate in various chemical reactions makes it a valuable component in the synthesis of a diverse array of chemical products.
Used in Agrochemical Development:
4-Pentene-1-sulfonamide is also used in the development of agrochemicals. Its antimicrobial and antibacterial properties make it a potential candidate for use in the creation of pesticides, fungicides, and other agricultural chemicals aimed at protecting crops and enhancing agricultural productivity.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, 4-Pentene-1-sulfonamide is employed for its potential applications in the discovery and design of new pharmaceutical agents. Its chemical properties and reactivity contribute to the advancement of drug development, particularly in the synthesis of compounds with therapeutic potential.
Overall, 4-Pentene-1-sulfonamide is a multifaceted chemical with applications spanning across various industries, from pharmaceuticals to agrochemicals, highlighting its importance in the synthesis of a broad spectrum of organic compounds.

Upstream product

• 60154-77-0 pent-4-ene-1-sulfonyl chloride 
• 1119-51-3 bromopentene 

Downstream Products

• 1027176-22-2 SO₂NH₂C₂HIC₆H₅(CH₂)3 
• 1450789-69-1 tert-butyl (3-((pent-4-en-1-ylsulfonyl)carbamoyl)phenyl)carbamate 
• 1450789-70-4 tert-butyl (4-((pent-4-en-1-ylsulfonyl)carbamoyl)phenyl)carbamate 
• 1450789-63-5 tert-butyl ((S)-1-(((S)-1-(4-((6-methoxy-2-phenylpyrimidin-4-yl)oxy)-3-vinylphenyl)-2-oxo-2-((2-((pent-4-en-1-ylsulfonyl)carbamoyl)phenyl)amino)ethyl)amino)-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
• 1450789-92-0 tert-butyl ((S)-1-(((R)-1-(4-((6-methoxy-2-phenylpyrimidin-4-yl)oxy)-3-vinylphenyl)-2-oxo-2-((2-((pent-4-en-1-ylsulfonyl)carbamoyl)phenyl)amino)ethyl)amino)-3,3-dimethyl-1-oxobutan-2-yl)carbamate 

Relevant academic research and scientific papers

Ruthenium(ii)-catalyzed intermolecular annulation of alkenyl sulfonamides with alkynes: Access to bicyclic sultams

A ruthenium-catalyzed allylic C(sp3)-H activation strategy has been employed to develop an intermolecular coupling of alkenyl sulfonamides with alkynes. This protocol features the diastereoselective construction of [3.3.0] and [4.3.0] bicyclic sultams in one step.

Synthesis of Sultams and Cyclic N-Sulfonyl Ketimines via Iron-Catalyzed Intramolecular Aliphatic C-H Amidation

Cyclic sulfonamides (sultams) play a unique role in drug discovery and synthetic chemistry. A direct synthesis of sultams by an intramolecular C(sp3)-H amidation reaction using an iron complex in situ derived from Fe(ClO4)2 and aminopyridine ligand is reported. This strategy features a readily available catalyst and tolerates a broad variety of substrates as demonstrated by 22 examples (up to 89% yield). A one-pot iron-catalyzed amidation/oxidation procedure for the synthesis of cyclic N-sulfonyl ketimines is also realized with up to 92% yield (eight examples). The synthetic utility of the method is validated by a gram-scale reaction and derivatization of the products to ring-fused sultams.

COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, (I) and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Metal-free intramolecular aziridination of alkenes using hypervalent iodine based sulfonyliminoiodanes

(Figure presented) Intramolecular aziridination of alkenyl sulfonyliminoiodanes occurs thermally In the absence of conventional metal catalysts such as Rh(II) and Cu(II). In rigid molecular systems, conversions are near quantitative. The scope of the nonm

Rhodium(II)-catalyzed aziridination of allyl-substituted sulfonamides and carbamates

Several unsaturated sulfonamides underwent intramolecular aziridination when treated with PhI-(OAc)2, MgO, and catalytic Rh 2(OAc)4 to give bicyclic aziridines in excellent yield. Treatment of the resulting azabicyclic sul

Synthesis of cyclic sulfonamides via intramolecular copper-catalyzed reaction of unsaturated iminoiodinanes

(equation presented) Olefinic primary sulfonamides were treated with iodebenzene diacetate and potassium hydroxide in methanol to give intermediate iminoiodinanes. Catalytic copper(I) or (II) triflate then provided intramolecular nitrene delivery leading to aziridene formation except in one case where a rare copper-catalyzed C-H insertion was observed. The aziridines could be opened by various nucleophiles (methanol, thiophenol, allylmagnesium bromide, benzylamine) to give the corresponding substituted cyclic sulfonamides.